BIOPOR Bioporto A/S

Managers’ transactions

Managers’ transactions

April 25, 2025

Announcement no. 13

                                                                        

Managers’ transactions

In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them.

1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameJens Due Olsen
2 Reason for the notification 
a)   Position/statusChair of the Board of Directors of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 2,984,629
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue
  
1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameHenrik Juul
2 Reason for the notification 
a)   Position/statusVice Chair of the Board of Directors of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
a)   Nature of the transactionSubscription of new shares in connection with private placement
b)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 746,157
c)   Aggregated informationn/a





d)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
e)   Place of the transactionOutside a trading venue
  
1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NamePeter Mørch Eriksen
2 Reason for the notification 
a)   Position/statusChief Executive Officer of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 373,078
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue



1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameGry Husby Larsen
2 Reason for the notification 
a)   Position/statusChief Legal Officer of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 186,539
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue



1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameNiels Høy Nielsen
2 Reason for the notification 
a)   Position/statusChief Financial Officer of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 186,539
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue

To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on /investor-contact/.

For further information, please contact:

Hanne S. Foss, Head of Investor Relations, BioPorto, , C:

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit .

Attachment



EN
25/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

Ledende medarbejderes transaktioner

Ledende medarbejderes transaktioner 25. april 2025Meddelelse nr. 13                                                                          Ledende medarbejderes transaktioner I forbindelse med gennemførelsen af BioPorto A/S' rettede emission, som beskrevet i selskabsmeddelelse nr. 12, har BioPorto A/S i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget indberetning af nedenstående transaktioner vedrørende aktier i BioPorto A/S foretaget af personer med ledelsesansvar i BioPorto A/S og/eller nærtstående til disse. 1 Nærmere oplysninger om personen med ledelsesansvar/persone...

 PRESS RELEASE

Managers’ transactions

Managers’ transactions April 25, 2025Announcement no. 13                                                                          Managers’ transactions In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them. 1 Details of the person discharging managerial responsibili...

 PRESS RELEASE

BioPorto A/S rejser 33,5 mio. kr. i ny kapitalrunde - Ændring i antal ...

BioPorto A/S rejser 33,5 mio. kr. i ny kapitalrunde - Ændring i antal aktier og stemmer 25. april 2025Meddelelse nr. 12                                                                          BioPorto A/S rejser 33,5 mio. kr. i ny kapitalrunde - Ændring i antal aktier og stemmer Gennemførelse af kapitalforhøjelse København, Danmark, 25. april 2025, (GLOBE NEWSWIRE) - Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR), en in-vitro diagnostisk virksomhed med fokus på tidlig identifikation og vurdering af akut nyreskade (AKI), besluttede den 15. april 2025 at udstede...

 PRESS RELEASE

BioPorto A/S raises DKK 33.5 million in new capital round - Change of ...

BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes April 25, 2025Announcement no. 12                                                                          BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes Completion of share capital increase COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), decided on Ap...

 PRESS RELEASE

Correction: Rettet emission af 25.000.000 nye aktier fuldt tegnet – br...

Correction: Rettet emission af 25.000.000 nye aktier fuldt tegnet – bruttoprovenu på 33,5 mio. kr. til BioPorto A/S 15. april 2025Meddelelse nr. 11                                                                          Rettet emission af 25.000.000 nye aktier fuldt tegnet – bruttoprovenu på 33,5 mio. kr. til BioPorto A/S København, Danmark, 15. april 2025, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto eller Selskabet) (CPH:BIOPOR), en in-vitro diagnostisk virksomhed med fokus på tidlig identifikation og vurdering af akut nyreskade (AKI), meddeler, at en rettet emission af 25.000.000 nye...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch